JP2004534057A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534057A5
JP2004534057A5 JP2003503214A JP2003503214A JP2004534057A5 JP 2004534057 A5 JP2004534057 A5 JP 2004534057A5 JP 2003503214 A JP2003503214 A JP 2003503214A JP 2003503214 A JP2003503214 A JP 2003503214A JP 2004534057 A5 JP2004534057 A5 JP 2004534057A5
Authority
JP
Japan
Prior art keywords
dosage form
prodrug
auc
gaba analog
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003503214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/018701 external-priority patent/WO2002100392A1/en
Publication of JP2004534057A publication Critical patent/JP2004534057A/ja
Publication of JP2004534057A5 publication Critical patent/JP2004534057A5/ja
Pending legal-status Critical Current

Links

JP2003503214A 2001-06-11 2002-06-11 低毒性を示す経口投与剤形のｇａｂａ類似体プロドラッグ Pending JP2004534057A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29752101P 2001-06-11 2001-06-11
US29851401P 2001-06-14 2001-06-14
US36609002P 2002-03-19 2002-03-19
PCT/US2002/018701 WO2002100392A1 (en) 2001-06-11 2002-06-11 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity

Publications (2)

Publication Number Publication Date
JP2004534057A JP2004534057A (ja) 2004-11-11
JP2004534057A5 true JP2004534057A5 (https=) 2005-12-22

Family

ID=27404495

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003516067A Expired - Lifetime JP4216713B2 (ja) 2001-06-11 2002-06-11 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
JP2003503214A Pending JP2004534057A (ja) 2001-06-11 2002-06-11 低毒性を示す経口投与剤形のｇａｂａ類似体プロドラッグ
JP2008171250A Withdrawn JP2009051822A (ja) 2001-06-11 2008-06-30 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
JP2008171589A Expired - Lifetime JP5001227B2 (ja) 2001-06-11 2008-06-30 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003516067A Expired - Lifetime JP4216713B2 (ja) 2001-06-11 2002-06-11 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008171250A Withdrawn JP2009051822A (ja) 2001-06-11 2008-06-30 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用
JP2008171589A Expired - Lifetime JP5001227B2 (ja) 2001-06-11 2008-06-30 Ｇａｂａ類似体のプロドラッグ、組成物およびその使用

Country Status (20)

Country Link
US (2) US6833140B2 (https=)
EP (4) EP1404310A4 (https=)
JP (4) JP4216713B2 (https=)
KR (5) KR100958552B1 (https=)
CN (1) CN1533270A (https=)
AT (2) ATE540678T1 (https=)
AU (4) AU2002345664C1 (https=)
CA (2) CA2449729C (https=)
CY (1) CY1107894T1 (https=)
DE (1) DE60223923T3 (https=)
DK (1) DK1404324T4 (https=)
ES (2) ES2296956T5 (https=)
HU (2) HUP0400183A2 (https=)
IL (5) IL159299A0 (https=)
MX (2) MXPA03011565A (https=)
NO (4) NO333756B1 (https=)
NZ (1) NZ567711A (https=)
PT (1) PT1404324E (https=)
WO (2) WO2002100392A1 (https=)
ZA (1) ZA200309679B (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE271864T1 (de) * 1998-05-15 2004-08-15 Warner Lambert Co Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211538A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
WO2002028411A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
WO2003055525A1 (fr) * 2001-12-25 2003-07-10 Takeda Chemical Industries, Ltd. Preparations contenant un acide
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US8641987B2 (en) 2003-01-24 2014-02-04 Applied Biosystems, Llc Sample chamber array and method for processing a biological sample
JP2006522146A (ja) * 2003-03-31 2006-09-28 ゼノポート，インコーポレイティド Ｇａｂａ類似体のプロドラッグを使用するのぼせの治療または予防
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
EP2354120A1 (en) * 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
PL1660440T3 (pl) * 2003-08-20 2012-07-31 Xenoport Inc Proleki acyloksyalkilokarbaminianowe, sposoby syntezy i zastosowanie
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
AU2004274002B2 (en) * 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
PT1677767E (pt) * 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
CN1902175B (zh) * 2003-12-30 2012-08-22 什诺波特有限公司 酰氧基烃基氨基甲酸酯前药及其中间体的合成
EP2371815A1 (en) * 2003-12-30 2011-10-05 XenoPort, Inc. Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
CA2570255A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
EP1740211A2 (en) * 2004-04-20 2007-01-10 Pfizer Products Incorporated Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
CA2597910A1 (en) * 2005-02-15 2006-08-24 Jazz Pharmaceuticals, Inc. Dosage form and method for sustained release of a substituted pyrazine compound
WO2007002013A2 (en) * 2005-06-20 2007-01-04 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
WO2007027477A2 (en) * 2005-08-23 2007-03-08 Xenoport, Inc. Treating vulvodynia using prodrugs of gaba analogs
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
BRPI0615300A2 (pt) * 2005-08-31 2009-07-14 Wyeth Corp composto; composição farmacêutica; método para a preparação, tratamento ou controle de infecções bacterianas em animais de sangue quente; uso de um composto; e método para a preparação de compostos representados pela fórmula (i)
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7879906B2 (en) 2006-11-24 2011-02-01 Anchen Laboratories, Inc. GABA analogs, compositions and methods for manufacturing thereof
EP2101585A4 (en) * 2006-11-30 2011-06-15 Cenerx Biopharma Inc PIVAGABIN DIALKYLAMINOAL CYLTERS AS A MEDICAMENT FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2673545A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids
WO2008157408A2 (en) * 2007-06-15 2008-12-24 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
CA2694982C (en) 2007-07-20 2013-06-25 Amyris Biotechnologies, Inc. Fuel compositions comprising tetramethylcyclohexane
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
WO2010063002A2 (en) 2008-11-26 2010-06-03 Teva Pharmaceutical Industries Ltd. Processes for the preparation and purification of gabapentin enacarbil
EP2404588A4 (en) 2009-03-02 2012-08-01 Astellas Pharma Inc PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION
AU2010221167B2 (en) 2009-03-06 2014-04-03 Xenoport, Inc. Oral dosage forms having a high loading of a gabapentin prodrug
WO2011101245A1 (en) 2010-02-18 2011-08-25 Nicox S.A. Nitric oxide releasing compounds for the treatment of neuropathic pain
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2013163889A1 (en) * 2012-05-03 2013-11-07 Dsm Ip Assets B.V. New intermediate compound for preparing vitamin b6
US20150158809A9 (en) 2013-02-26 2015-06-11 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
PL4001272T3 (pl) * 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
CN114306234A (zh) * 2021-12-23 2022-04-12 江苏百奥信康医药科技有限公司 一种含有加巴喷丁复合物的tpgs胶束口服液及其制备方法

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
GB1364672A (en) 1971-06-09 1974-08-29 Beecham Group Ltd Penicillins
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992414A (en) * 1973-12-20 1976-11-16 Lever Brothers Company Process for the preparation of selectively halogenated ketals
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4036064A (en) * 1975-09-11 1977-07-19 Gilford Instrument Laboratories, Inc. Pipette device
US4093571A (en) * 1976-01-14 1978-06-06 Celanese Corporation Process for making porous metal containing powder coating compositions
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4189571A (en) * 1978-02-07 1980-02-19 Fisons Limited Esters of cromoglycates
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
FR2476087A1 (fr) * 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
JPS57193489A (en) * 1981-05-21 1982-11-27 Fujisawa Pharmaceut Co Ltd Syn-isomer of 7-substituted-3-cephem-4-carboxylic acid ester and its preparation
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4760057A (en) * 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
EP0130119B1 (en) * 1983-06-23 1988-11-09 Merck & Co. Inc. (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
DE3479397D1 (en) * 1983-10-05 1989-09-21 Merck Frosst Canada Inc Benzoûa¨phenothiazines and hydro-derivatives and pharmaceutical compositions containing them
US4611056A (en) * 1983-10-05 1986-09-09 Merck Frosst Canada, Inc. Benzo[A]phenothiazines and hydro-derivatives
EP0138481B1 (en) * 1983-10-05 1991-06-26 Merck Frosst Canada Inc. Leukotriene biosynthesis inhibitors
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US5051448A (en) * 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084169A (en) 1989-09-19 1992-01-28 The University Of Colorado Foundation, Inc. Stationary magnetically stabilized fluidized bed for protein separation and purification
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
GB9001405D0 (en) * 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
JPH04103574A (ja) * 1990-08-22 1992-04-06 Kumiai Chem Ind Co Ltd ピリミジン誘導体及び除草剤
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
TW209174B (https=) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9204918D0 (en) 1992-03-06 1992-04-22 Nycomed As Chemical compounds
JP3856816B2 (ja) * 1992-05-20 2006-12-13 ノースウェスターン ユニヴァーシティ 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
KR960704887A (ko) 1993-10-14 1996-10-09 챨스 엠. 브록 퀴놀리지논형 화합물 (Quinolizinone type compounds)
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
EP0888325B1 (en) 1996-02-07 2002-05-29 Warner-Lambert Company Novel cyclic amino acids as pharmaceutical agents
HU224720B1 (en) 1996-03-14 2006-01-30 Warner Lambert Co Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
WO1997033859A1 (en) * 1996-03-14 1997-09-18 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
SK8599A3 (en) 1996-07-30 2000-03-13 Arris Pharm Corp Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal
US5962473A (en) 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
ATE361909T1 (de) 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
IL133625A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
ATE323067T1 (de) 1997-10-27 2006-04-15 Warner Lambert Co Zyklische aminosäuren und deren derivate als arzneimittel
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
SI1045839T1 (en) * 1997-12-16 2004-06-30 Warner-Lambert Company Llc Novel amines as pharmaceutical agents
CA2304967C (en) 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2309354A1 (en) 1998-01-23 1999-07-29 Leslie Magnus-Miller Gabapentin and its derivatives for the treatment of muscular and skeletal pain
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6245801B1 (en) 1998-09-14 2001-06-12 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
CA2344407C (en) 1998-10-16 2007-01-09 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
US6627771B1 (en) 1998-11-25 2003-09-30 Pfizer Inc Gamma amino butyric and acid analogs
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
EP1180102B9 (en) 1999-05-27 2005-03-02 Pfizer Products Inc. Mutual prodrugs of amlodipine and atorvastatin
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
WO2001042191A1 (en) 1999-12-08 2001-06-14 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
IL150929A0 (en) 2000-01-28 2003-06-24 Rohm & Haas Pharmaceutical compounds comprising a pharmaceutically active moiety and a moiety comprising a substituent that enhances its properties
AU2001243253A1 (en) 2000-02-24 2001-09-03 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
PL204753B1 (pl) 2000-05-25 2010-02-26 Hoffmann La Roche Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
IL152770A0 (en) 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
AU2001268951A1 (en) 2000-07-07 2002-01-21 Novo-Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1301516B1 (en) 2000-07-07 2006-03-22 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028411A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Compounds for sustained release of orally delivered drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
MXPA03009130A (es) 2000-10-20 2004-02-26 Biocryst Pharm Inc Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
US6683112B2 (en) * 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) * 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2002062766A2 (en) * 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
MXPA03012041A (es) 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
EP2327409A1 (en) 2001-07-13 2011-06-01 Paratek Pharmaceuticals, Inc. Tetracycline compound having target therapeutic activities
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1651963A4 (en) * 2003-07-03 2007-03-21 Xenoport Inc MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker

Similar Documents

Publication Publication Date Title
JP2004534057A5 (https=)
EP1246668B1 (en) An rapid acting freeze dired oral pharmaceutical composition for treating migraine
BRPI0711168A2 (pt) composição transmucosal
JP2005515966A5 (https=)
CA2066403A1 (en) Transmucosal dosage form
CA2529746A1 (en) Oral extended-release composition
RU2010152012A (ru) Таблетируемые жевательные резинки
JP2010502591A5 (https=)
JPH0759496B2 (ja) 歯周病治療剤
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP7702950B2 (ja) アゴメラチンを含有する経粘膜治療システム
EP3641759A1 (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
JP2009517411A5 (https=)
CN101563071A (zh) 尼古丁经口粘膜剂型
CN113597303B (zh) 含有阿戈美拉汀的经粘膜治疗系统
JP2005522467A5 (https=)
US20020132002A1 (en) Sustained release pharmaceutical formulation
KR101771786B1 (ko) 서방성 구강 약물 전달체
JP2024540936A (ja) 増大された安定性プロファイルを有する医薬組成物
TW202310840A (zh) 阿哌沙班膜及其使用方法
JP2003519641A (ja) 局所的薬用生体接着剤組成物、並びにその使用法および調製法
JP2006528160A (ja) 抗血栓性化合物の口腔分散性医薬組成物
JP2002541085A5 (https=)
JP2009507850A5 (https=)
HK40089892A (zh) 含有阿戈美拉汀的经粘膜治疗系统